Telix Pharmaceuticals (TLPPF) Long-Term Investments (2024 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Long-Term Investments for 3 consecutive years, with -$1.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Long-Term Investments changed N/A year-over-year to -$1.0 million in Q2 2026; TTM through Jun 2026 was -$1.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $342.4 million, up 80.83% from the prior year.
• Long-Term Investments was -$1.0 million for Q2 2026 at Telix Pharmaceuticals, down from $342.4 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $342.4 million in Q4 2025 and troughed at -$1.0 million in Q2 2026.
• A 3-year average of $176.9 million and a median of $189.4 million in 2024 frame the typical range for Long-Term Investments.
• The widest YoY moves for Long-Term Investments: up 80.83% in 2025, down 80.83% in 2025.
• Over 3 years, Long-Term Investments stood at $189.4 million in 2024, then surged by 80.83% to $342.4 million in 2025, then sank by 100.29% to -$1.0 million in 2026.
• The last three Long-Term Investments figures came in at -$1.0 million (Q2 2026), $342.4 million (Q4 2025), and $189.4 million (Q4 2024), per Business Quant data.